Pretreatment pupillary reactivity is associated with outcome of Repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD)
Journal of Affective Disorders · 2023
DOI: 10.1016/j.jad.2023.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2023. Verfasst von Cole Citrenbaum und 14 weiteren Autor:innen. Beteiligte Einrichtung: TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA; Depar…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Reflex, Pupillary, Transcranial Magnetic Stimulation, Parasympathetic Nervous System. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Mental Health.
Abstract (Originalsprache)
BACKGROUND: Pre-treatment biomarkers for outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD) have proven elusive. One promising family of biomarkers involves the autonomic nervous system (ANS), which is dysregulated in individuals with MDD. METHODS: We examined the relationship between the pre-treatment pupillary light reflex (PLR) and rTMS outcome in 51 MDD patients. Outcome was measured as the percent change in the 30-item Inventory of Depressive Symptomatology Self Rated (IDS-SR) score from baseline to treatment 30. RESULTS: Patients showed significant improvement with rTMS treatment. There was a significant correlation between baseline pupillary Constriction Amplitude (CA) and clinical improvement over the treatment course (R = 0.41, p = 0.003). LIMITATIONS: We examined a limited number of subjects who received heterogeneous treatment protocols. Almost all patients in the study received psychotropic medications concomitant with rTMS treatment. CONCLUSION: PLR measured before treatment may be a predictive biomarker for clinical improvement from rTMS in subjects with MDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of…
- UC San Diego, La Jolla, CA 92093, USA.
Förderung
- National Institute of Mental Health
Zitieren
APA
Citrenbaum, C., Corlier, J., Ngo, D., Vince-Cruz, N., Wilson, A., Wilke, S., Krantz, D., Tadayonnejad, R., Ginder, N., Levitt, J., Lee, J. H., Strouse, T., Corse, A., Vyas, P., & Leuchter, A. F. (2023). Pretreatment pupillary reactivity is associated with outcome of Repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD). Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.07.008
Vancouver
Citrenbaum C, Corlier J, Ngo D, Vince-Cruz N, Wilson A, Wilke S, et al. Pretreatment pupillary reactivity is associated with outcome of Repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD). Journal of Affective Disorders. 2023. doi:10.1016/j.jad.2023.07.008
BibTeX
@article{Citrenbaum2023,
author = {Citrenbaum, Cole and Corlier, Juliana and Ngo, Doan and Vince-Cruz, Nikita and Wilson, Andrew and Wilke, Scott and Krantz, David and Tadayonnejad, Reza and Ginder, Nathaniel and Levitt, Jennifer and Lee, John H and Strouse, Thomas and Corse, Andrew and Vyas, Pooja and Leuchter, Andrew F},
title = {Pretreatment pupillary reactivity is associated with outcome of Repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD)},
journal = {Journal of Affective Disorders},
year = {2023},
doi = {10.1016/j.jad.2023.07.008}
}
EUVIMED